Short-Term Incubation of H9c2 Cardiomyocytes with Cannabigerol Attenuates Diacylglycerol Accumulation in Lipid Overload Conditions

pubmed logo

“Fatty acids (FAs) play a crucial role in human physiology, including energy production and serving as signaling molecules. However, a dysregulation in their balance can lead to multiple disorders, such as obesity and metabolic syndrome. These pathological conditions alter the balance between the heart’s energetic substrates, promoting an increased reliance on FAs and decreased cardiac efficiency.

A therapeutic application of a non-psychotropic phytocannabinoid, cannabigerol (CBG), seems to be a promising target since it interacts with different receptors and ion channels, including cannabinoid receptors-CB1 and CB2, α2 adrenoceptor, or 5-hydroxytryptamine receptor.

Therefore, in the current study, we evaluated a concentration-dependent effect of CBG (2.5 µM, 5 µM, and 10 µM) on H9c2 cardiomyocytes in lipid overload conditions. Gas-liquid chromatography and Western blotting techniques were used to determine the cellular lipid content and the level of selected proteins involved in FA metabolism, glucose transport, and the insulin signaling pathway. The glucose uptake assay was performed using a colorimetric method.

Eighteen-hour CBG treatment in the highest concentration (10 µM) significantly diminished the accumulation of diacylglycerols (DAGs) and the saturation status of this lipid fraction. Moreover, the same concentration of CBG markedly decreased the level of FA transporters, namely fatty acid translocase (CD36) and plasma membrane fatty acid-binding protein (FABPpm), in the presence of palmitate (PA) in the culture medium.

The results of our experiment suggest that CBG can significantly modulate lipid storage and composition in cardiomyocytes, thereby protecting against lipid-induced cellular dysfunction.”

https://pubmed.ncbi.nlm.nih.gov/40643519/

“In our research, we presented evidence suggesting that CBG treatment, especially in higher concentrations (10 µM), may offer substantial benefits in the states associated with excessive lipid availability, which was demonstrated in the H9c2 cell model. The results obtained in our experiment suggest that CBG possesses the ability to alter the metabolism of H9c2 cells by influencing FA storage and utilization while also attenuating the inflammatory pathways activated in a high-lipid environment. These findings indicate that CBG may represent a promising therapeutic candidate for further investigation concerning lipotoxicity and insulin resistance development. Moreover, CBG is predisposed to be a metabolic modulator by altering the levels and cellular location of CD36, a major regulator of myocardial lipid metabolism and a therapeutic target for metabolic disturbances.”

https://www.mdpi.com/2073-4409/14/13/998

Leave a Reply

Your email address will not be published. Required fields are marked *